How to select the most valuable anticancer drugs for reimbursement? Experience of ESMO and WHOAuthor:Poliakova D. Т. 13, № 1 (49)
The role of T790M mutation in first- and second-line therapy of patients with EGFR-positive non-small cell lung cancerAuthors: Storozhenko S.A. Shparyk Ya.V. Т. 13, № 1 (49)
Hepatocellular carcinoma: epidemiology, diagnostic, treatmentAuthors: Lukashenko A. Patsko V. Ostapenko Y. Cherchenko K. Т. 13, № 1 (49)
Assessment of overall survival obtained from the real-world study of using the combination of palbociclib with aromatase inhibitors as a first-line treatment of HR+/HER2− metastatic breast cancer
Metastatic bone lesions: molecular mechanisms as new avenues of therapeutic influence. Literature reviewAuthors: Solodyannуkova O.I. Bankovska N.V. Shypko A.F. Danylenko V.V.... Т. 13, № 1 (49)
